Paper Details

  1. Home
  2. Paper Details

Use of magnesium hydroxide and low magnesium dialysate does not permit reduction of aluminum hydroxide during continuous ambulatory peritoneal dialysis.

Author: BodvarssonM, DiefendorfA S, Galicka-PiskorskaG, JenningsA E, LeveyA S, SimonG M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Substituting magnesium hydroxide for aluminum hydroxide as a phosphate binder in patients on CAPD failed to reduce the aluminum dose in most patients.
Paper Details　
Original Abstract of the Article :
In an effort to reduce the ingestion of aluminum in phosphate-binding antacids, we treated seven patients on continuous ambulatory peritoneal dialysis (CAPD) with low magnesium dialysate and phosphate binders containing both aluminum and magnesium hydroxide. The total amount of phosphate binders pre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0272-6386(86)80024-5

データ提供：米国国立医学図書館（NLM）

The Challenge of Aluminum Reduction in Dialysis

Continuous ambulatory peritoneal dialysis (CAPD) is a vital treatment for individuals with kidney failure. However, managing aluminum levels in these patients can be complex, especially when using phosphate-binding antacids that contain aluminum. This study investigates the effectiveness of using magnesium hydroxide instead of aluminum hydroxide as a phosphate binder in CAPD patients.

Magnesium Hydroxide: Not a Simple Aluminum Replacement

The study involved seven CAPD patients who were prescribed low-magnesium dialysate and phosphate binders containing both aluminum and magnesium hydroxide. The results were not encouraging. The dose of magnesium hydroxide was limited by intolerable gastrointestinal side effects in most patients, and one patient developed symptomatic hypermagnesemia. Even when magnesium hydroxide was administered in tolerable doses, the mean aluminum dose was not significantly reduced compared to using aluminum hydroxide alone.

A Reminder of Treatment Complexity

This research highlights the challenges of finding effective and safe alternatives to aluminum-containing phosphate binders in CAPD patients. The study emphasizes the need for individualized treatment approaches and a careful consideration of potential side effects when managing aluminum levels in these patients. Just as a camel needs to adapt its journey to changing desert conditions, clinicians must remain vigilant in their efforts to optimize treatment plans for individuals with kidney failure.

Dr.Camel's Conclusion

This study reveals the limitations of using magnesium hydroxide as a substitute for aluminum hydroxide in CAPD patients. The findings highlight the complexity of managing aluminum levels in these patients and underscore the need for ongoing research to identify safe and effective alternatives to aluminum-containing phosphate binders.

Date :
  1. Date Completed 1986-10-15
  2. Date Revised 2019-08-15
Further Info :

Pubmed ID

3752074

DOI: Digital Object Identifier

10.1016/s0272-6386(86)80024-5

Related Literature

Article Analysis
・Side Effects of magnesium hydroxide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.